BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53
6827 results:

  • 1. A narrative review on therapeutic potential of naringenin in colorectal cancer: Focusing on molecular and biochemical processes.
    Zamanian MY; Golmohammadi M; Abdullaev B; García MO; Alazbjee AAA; Kumar A; Mohaamed SS; Hussien BM; Khalaj F; Hodaei SM; Shirsalimi N; Moriasi G
    Cell Biochem Funct; 2024 Apr; 42(3):e4011. PubMed ID: 38583080
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Biogenic Zinc Oxide Nanoparticles synthesized from
    Berehu HM; Patnaik S
    Nanotheranostics; 2024; 8(3):312-329. PubMed ID: 38577319
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Urocortin-1 promotes colorectal cancer cell migration and proliferation and inhibits apoptosis via inhibition of the p53 signaling pathway.
    Guo X; Li Y; Chen X; Sun B; Guo X
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):163. PubMed ID: 38546882
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Organosulfur Compounds in colorectal cancer Prevention and Progression.
    McAlpine PL; Fernández J; Villar CJ; Lombó F
    Nutrients; 2024 Mar; 16(6):. PubMed ID: 38542713
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Comparative analysis of single-cell transcriptome reveals heterogeneity and commonality in the immune microenvironment of colorectal cancer and inflammatory bowel disease.
    Lv H; Mu Y; Zhang C; Zhao M; Jiang P; Xiao S; Sun H; Wu N; Sun D; Jin Y
    Front Immunol; 2024; 15():1356075. PubMed ID: 38529274
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Prediction of potential mechanisms of rhubarb therapy for colorectal cancer based on network pharmacological analysis and molecular docking.
    Yang F; Li X; Zhang Y; Ren Y; Zhang J; Xiao K
    Medicine (Baltimore); 2024 Mar; 103(12):e37477. PubMed ID: 38518016
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib.
    Li H; Feng H; Zhang T; Wu J; Shen X; Xu S; Xu L; Wang S; Zhang Y; Jia W; Ji X; Cheng X; Zhao R
    Mol Cancer; 2024 Mar; 23(1):59. PubMed ID: 38515149
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Bis-arylidene oxindoles for colorectal cancer nanotherapy.
    Bhattacharyya T; Mishra T; Das D; Adhikari SS; Banerjee R
    Bioorg Chem; 2024 May; 146():107294. PubMed ID: 38507997
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques.
    Deycmar S; Johnson BJ; Ray K; Schaaf GW; Ryan DP; Cullin C; Dozier BL; Ferguson B; Bimber BN; Olson JD; Caudell DL; Whitlow CT; Solingapuram Sai KK; Romero EC; Villinger FJ; Burgos AG; Ainsworth HC; Miller LD; Hawkins GA; Chou JW; Gomes B; Hettich M; Ceppi M; Charo J; Cline JM
    J Transl Med; 2024 Mar; 22(1):292. PubMed ID: 38504345
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.
    Zhou YW; Zhao X; Ni L; Cao P; Leng WB; Zhu Q; Gou HF; Zhang J; Li XF; Qiu M
    Int Immunopharmacol; 2024 Apr; 131():111887. PubMed ID: 38503018
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Differential genetic mutations and immune cell infiltration in high- and low-risk STAD: Implications for prognosis and immunotherapy efficacy.
    Deng YY; Sun Y; Wu SJ; Zhang TY; Yang J; Liu K
    J Cell Mol Med; 2024 Apr; 28(7):e18174. PubMed ID: 38494839
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Negative prognostic impact of Co-mutations in TGFβ and tp53 pathways in surgically resected rectal tumors following neoadjuvant chemoradiotherapy.
    Qian C; Yang W; Li M; Feng Y; Dai N; Luo H; Jian D; Li X; Yang Y; He Y; Wang D; Li C; Xiao H
    Eur J Surg Oncol; 2024 Apr; 50(4):108242. PubMed ID: 38460248
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Changes in chromatin accessibility and transcriptional landscape induced by HDAC inhibitors in tp53 mutated patient-derived colon cancer organoids.
    Gagliano T; Kerschbamer E; Baccarani U; Minisini M; Di Giorgio E; Dalla E; Weichenberger CX; Cherchi V; Terrosu G; Brancolini C
    Biomed Pharmacother; 2024 Apr; 173():116374. PubMed ID: 38447451
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Evaluating the role of wound-healing genes in conjunction with stool routine and serum tumor markers for colorectal cancer diagnosis and prognostic implications.
    Yu K; Fang X
    Int Wound J; 2024 Mar; 21(3):e14768. PubMed ID: 38446012
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.
    Liu H; Zhou D; Liu D; Xu X; Zhang K; Hu R; Xiong P; Wang C; Zeng X; Wang L; Zhang S
    Cell Death Dis; 2024 Mar; 15(3):187. PubMed ID: 38443386
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. KCTD15 acts as an anti-tumor factor in colorectal cancer cells downstream of the demethylase FTO and the m6A reader YTHDF2.
    Zhang FY; Wu L; Zhang TN; Chen HH
    Commun Biol; 2024 Mar; 7(1):262. PubMed ID: 38438714
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K‑562 and colorectal HCT‑116 cancer cells.
    Kakafika MG; Lyta AA; Gavriilidis GI; Tsiftsoglou SA; Miliotou AN; Pappas IS; Vizirianakis IS; Papadopoulou LC; Tsiftsoglou AS
    Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38426621
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Morindone as a potential therapeutic compound targeting tp53 and KRAS mutations in colorectal cancer cells.
    Chee CW; Mohd Hashim N; Nor Rashid N
    Chem Biol Interact; 2024 Apr; 392():110928. PubMed ID: 38423379
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. SOX17 enables immune evasion of early colorectal adenomas and cancers.
    Goto N; Westcott PMK; Goto S; Imada S; Taylor MS; Eng G; Braverman J; Deshpande V; Jacks T; Agudo J; Yilmaz ÖH
    Nature; 2024 Mar; 627(8004):636-645. PubMed ID: 38418875
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. cancer Risks Associated With
    Fortuno C; Feng BJ; Carroll C; Innella G; Kohlmann W; Lázaro C; Brunet J; Feliubadaló L; Iglesias S; Menéndez M; Teulé A; Ballinger ML; Thomas DM; Campbell A; Field M; Harris M; Kirk J; Pachter N; Poplawski N; Susman R; Tucker K; Wallis M; Williams R; Cops E; Goldgar D; ; James PA; Spurdle AB
    JCO Precis Oncol; 2024 Feb; 8():e2300453. PubMed ID: 38412388
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 342.